Novonesis account plan
biological solutions for sustainability
At a glance
Novonesis is a Danish biosolutions company (enzymes, cultures, probiotics, HMOs) with EUR 4,157.6 million of 2025 sales and 11,641 employees.
Novonesis (legal entity Novozymes A/S, listed as NSIS B on Nasdaq Copenhagen) makes enzymes, cultures, probiotics, yeast, proteins and human milk oligosaccharides (HMOs) by industrial fermentation, sold to food, health, household care, agriculture and energy producers. It was formed by the combination of Novozymes and Chr. Hansen on January 29, 2024. In 2025 it reported net sales of EUR 4,157.6 million, 7% organic growth, an adjusted EBITDA margin of 37.1% and net profit of EUR 583.6 million, with 11,641 employees at end-2025 (5,104 in Denmark). Novo Holdings A/S holds 25.5% of the shares and 63.4% of the votes.
Business units
Food & Health Biosolutions
45% of 2025 sales (EUR 1,867.3 million)Food ingredient and processing biosolutions plus health solutions, split into two sales areas. In 2025 it grew 8% organically with a 35.8% adjusted EBITDA margin; in 9M 2026 it grew 9% organically with a 37.0% margin.
Food & Beverages
about 33% of group sales in 2025 (EUR 1,372.5 million), computedCultures and enzymes for dairy, cheese, baking, meat, plant-based and beverage producers. Dairy innovation, high-protein fresh dairy and cheese conversion drove 12% organic growth in 9M 2026.
Human Health
about 12% of group sales in 2025 (EUR 494.8 million), computedProbiotics, HMOs and precision-fermented proteins for dietary supplements and early-life nutrition. It grew 10% in 2025 but was flat in 9M 2026 on weakness in the North American probiotic supplements market, and is now expected to slightly decline in 2026.
Planetary Health Biosolutions
55% of 2025 sales (EUR 2,290.3 million)Biosolutions that cut the use of fossil-based resources, chemicals and energy in detergents, fuels, agriculture and industrial processes. It grew 6% organically in 2025 with a 38.2% margin, and 6% in 9M 2026.
Household Care
about 19% of group sales in 2025 (EUR 801.2 million), computedEnzymes for laundry, dishwashing and industrial cleaning sold to detergent makers, with growth from emerging markets and local and regional players. It grew 7% organically in both 2025 and 9M 2026.
Agriculture, Energy & Tech
about 36% of group sales in 2025 (EUR 1,489.1 million), computedEnzymes and yeast for ethanol and biodiesel producers, feed enzymes and probiotics, plant biosolutions and bioprocessing aids for biopharma. Energy grew double-digit in 9M 2026, while Plant declined on weak US farm economics and Tech on biopharma order timing.
Strategic priorities
- GROW strategy 2030 targets
- Presented in August 2025, GROW targets 6-9% organic sales CAGR, an adjusted EBITDA margin of ~39% and adjusted ROIC excluding goodwill of ~16% by 2030.
- Outgrowing end markets
- Growth of the core comes from value-based pricing, penetration and sales synergies; pricing added close to 2 percentage points and synergies a good 1 point in 9M 2026.
- Emerging markets presence
- Emerging markets were 38% of 9M 2026 sales and are expected to grow faster than developed ones by 2030, helped by more local commercial presence and co-creation labs such as a detergent powder lab in India.
- AI and data across R&D and operations
- AlphaFold, Cradle models and quantum work with Kvantify are used in R&D; more than 600 AI ambassadors are to be trained, and the ERP system and data infrastructure are being upgraded.
- Emissions reduction
- The 2030 target is a 75% cut in scope 1 and 2 emissions from 2018; 67% had been achieved in 2025.
Latest results
In the first nine months of 2026, net sales reached EUR 3,375.6 million against EUR 3,161.0 million, with 7% organic growth (Q3: 6%). The adjusted EBITDA margin was 37.9%, 60 bps above 9M 2025, and net profit EUR 558.7 million. Food & Beverages grew 12% organically, while Human Health was flat on a weak North American probiotic supplements market. The 2026 outlook, raised in August from 5-7%, is confirmed at 7-8% organic growth with the adjusted EBITDA margin at the higher end of 37-38%.
Investments and deals
- Feed Enzyme Alliance buyout
- On June 2, 2025 it acquired dsm-firmenich's sales and distribution activities in the alliance for EUR 1,587.0 million, refinanced in March 2026 with EUR 1.7 billion of bonds rated A- by S&P.
- Production capacity expansion
- CAPEX is guided at the higher end of 12-14% of sales in 2026 for capacity expansion, up from 11.3% of sales in 2025.
- Plumino Precision Fermentation (Thailand)
- Acquired April 1, 2026 for EUR 41.3 million net of cash: a fermentation plant in Rayong with around 200 employees, to be expanded including for HMO production and expected to be commercially operational in 2027.
- MicroBioGen
- The remaining 77% of this Australian yeast-strain specialist was acquired October 1, 2026 for EUR 113.7 million in cash plus ~EUR 33 million deferred.
- Share buyback
- An inaugural EUR 1 billion multi-year buyback runs to end-2029, with EUR 75 million planned for 2026.
Challenges and risks
- Cyber risk
- A cyberattack causing material business disruption or data compromise is rated the higher-probability key risk.
- Geopolitical and trade uncertainty
- Tariffs, sanctions and supply disruptions are a key risk; US tariff refunds to customers had a minor negative effect on price in 2026.
- North American probiotic supplements
- Human Health was flat in 9M 2026 (Q3: -8%) on weakness in this market and customers' channel and product format shifts.
- Country exits
- Exiting Russia and Belarus and other countries cost around 1 percentage point of organic growth in 9M 2026.
- Regulation built for chemicals
- The CEO says biosolutions are still regulated under frameworks designed for traditional chemicals, which she calls a barrier to innovation.
What leadership says
“With strong sales and profitability, we continue to demonstrate the strength and resilience of Novonesis' diversified business... We remain confident in our full-year outlook, supported by a solid start to the fourth quarter.”
“We [represent] 1% to 5% of the cost of the products our customers produce, but we are a big enabler of the value they generate. This is why we are outgrowing all the markets we serve.”
“Now, we need a new framework that reflects today's science and solutions.”
“The worst thing you can do in an integration is to ever celebrate success.”
Where a supplier can help
- Capacity expansion projects
- CAPEX at the higher end of 12-14% of sales for capacity expansion, plus the Rayong plant expansion for HMO production, opens room for engineering, equipment and construction suppliers.
- ERP and data infrastructure upgrade
- The ongoing ERP and data infrastructure upgrade and the AI ambassador programme are entry points for IT, data and AI partners.
- Cybersecurity
- With cyberattack rated the higher-probability key risk, security and recovery providers can tie offers to the company's own risk ranking.
- Local commercial presence in emerging markets
- The goal of more local commercial presence in emerging markets supports partners in sales enablement, distribution and local application labs.
- Integrating acquisitions
- Folding in the Feed Enzyme Alliance, Plumino and MicroBioGen creates integration work in systems, supply chain and HR.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Novonesis?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Novonesis Annual Report 2025
- Novonesis (legal entity Novozymes A/S, listed as NSIS B on Nasdaq Copenhagen) is a pure biology player in enzymes, cultures, probiotics, yeast, proteins and HMOs, formed by the combination of Novozymes and Chr. Hansen on January 29, 2024; it has more than 11,000 employees (11,641 at end-2025) and its biosolutions reach more than two billion people every day.
- 2025 net sales were EUR 4,157.6 million with 7% organic sales growth (developed markets 6%, emerging markets 9%) and an adjusted EBITDA margin of 37.1%, both in line with the 2025 outlook; net profit was EUR 583.6 million and free cash flow before acquisitions EUR 770.4 million.
- Two divisions: Food & Health Biosolutions (45% of sales, 8% organic growth, 35.8% adjusted EBITDA margin) and Planetary Health Biosolutions (55% of sales, 6% organic growth, 38.2% margin); four sales areas: Food & Beverages, Human Health, Household Care and Agriculture, Energy & Tech.
- The GROW strategy (August 2025) sets 2030 targets of 6-9% organic sales CAGR, ~39% adjusted EBITDA margin and ~16% adjusted ROIC excluding goodwill, with a 75% cut in scope 1 and 2 emissions from 2018.
- In June 2025 it bought dsm-firmenich's share of the Feed Enzyme Alliance (purchase price EUR 1,587.0 million), financed by a EUR 1,470 million bridge loan; NIBD/EBITDA rose to 1.9x.
- R&D was 11% of sales, 33 new products were launched and 25% of revenue came from solutions developed in the last five years; AI (AlphaFold, Cradle, Kvantify quantum work) is used across R&D, production and sales forecasting, and an ERP upgrade is under way.
- 2026 outlook: 5-7% organic sales growth, adjusted EBITDA margin 37-38%, CAPEX 12-14% of sales for capacity expansion, NIBD/EBITDA ~1.7x at year end.
- Key risks named: cyberattack causing material business disruption, and global political and economic uncertainty (tariffs, sanctions, supply disruptions); the exit from Russia and Belarus cost around 1 percentage point of growth.
- Novo Holdings A/S holds 25.5% of the shares and 63.4% of the votes; Cees de Jong chairs the board, Ester Baiget is CEO and Rainer Lehmann CFO.
- Novonesis Interim report 9M 2026
- 9M 2026 net sales EUR 3,375.6 million (+7% in EUR) with 7% organic growth (Q3: 6%), including around 1 percentage point negative effect from exiting certain countries; pricing close to 2 points and sales synergies a good 1 point.
- Adjusted EBITDA EUR 1,279.3 million at a 37.9% margin (Q3: 38.3%), 60 bps above 9M 2025; net profit EUR 558.7 million; free cash flow before acquisitions EUR 557.1 million.
- Food & Beverages grew 12% organically (Q3: 14%), while Human Health was flat (Q3: -8%) on weakness in the North American probiotic supplements market and customers' channel and product format shifts; HMO kept growing strongly.
- Household Care grew 7% and Agriculture, Energy & Tech 5% (double-digit Energy; Plant hurt by weak US farm economics; Tech declined on biopharma order timing).
- 2026 outlook confirmed at 7-8% organic growth with high single-digit Q4 growth, adjusted EBITDA margin at the higher end of 37-38%, CAPEX at the higher end of 12-14% of sales; Human Health now expected to slightly decline.
- Acquired Plumino Precision Fermentation in Rayong, Thailand (April 1, EUR 41.3 million net of cash, around 200 employees) and the remaining 77% of yeast specialist MicroBioGen (October 1, EUR 113.7 million plus ~EUR 33 million deferred).
- Issued EUR 1.7 billion of bonds in March (A- rating from S&P) to refinance the Feed Enzyme Alliance bridge; NIBD/EBITDA 1.7x; EUR 14.8 million bought back of a EUR 75 million 2026 tranche of the EUR 1 billion buyback.
- Novonesis Interim report H1 2026
- H1 2026 net sales EUR 2,235.5 million (+7% in EUR) with 8% organic growth (Q2: 9%), including ~1.5 points negative from exiting certain countries; price close to 2 points, revenue synergies a good 1 point.
- Adjusted EBITDA EUR 842.2 million at 37.7% (Q2: 37.6%); adjusted net profit excluding PPA +8% to EUR 507.1 million; NIBD/EBITDA 1.8x.
- Full-year organic growth outlook raised from 5-7% to 7-8%, with the adjusted EBITDA margin expected at the higher end of 37-38%.
- Food & Beverages grew 11% and Human Health 4% (softer North American probiotic supplements); Household Care 8% (Q2: 12%) and Agriculture, Energy & Tech 6%, led by double-digit Energy.
- Latin America grew 18% organically (Q2: 22%); emerging markets 8% despite ~4 points of drag from country exits.
- Board approved an inaugural EUR 1 billion share buyback to run to end-2029 (Novo Holdings to sell pro rata to stay at ~25.5%) and an interim dividend of DKK 2.35 per share.
- Bought Plumino Precision Fermentation's plant in Rayong, Thailand, and agreed to buy the remaining 77% of MicroBioGen; from 2027, Q1 and Q3 interim reports become sales trading updates.
- Benefits by design: Novonesis CEO's strategy for sustainable growth (IMD CEO Dialogue Series)
- IMD's Jean-François Manzoni interviews Novonesis CEO Ester Baiget (October 2025) on the integration of Novozymes and Chr. Hansen, innovation, customers, sustainability and regulation.
- On the merger: "We're in a really, really good place", but "The worst thing you can do in an integration is to ever celebrate success"; employees chose which cultural "ingredients" to keep, and the new name signalled a new company rather than a takeover.
- The article puts Novonesis at almost 11,000 employees and annual sales of EUR 4bn, with an engagement score of 8.5 just over a year after the merger.
- Innovation rests on 10,000 patents and over 100,000 microbial strains, combined with AI, CRISPR and bioengineering: "We have a library of strengths - we don't have a pile of strengths."
- Value proposition: "We [represent] 1% to 5% of the cost of the products our customers produce, but we are a big enabler of the value they generate. This is why we are outgrowing all the markets we serve."
- Local co-creation labs (a detergent "powder lab" in India, a baking lab in Turkey) keep it close to regional customers, especially in household care.
- Regulation is the main barrier: biosolutions are still regulated under frameworks designed for chemicals; "Now, we need a new framework that reflects today's science and solutions."
- Ester Baiget, Ela Aposta no Brasil para Escalar um Mercado de Biossoluções de US$ 877 Bi (Forbes Agro)
- Forbes Brasil (Forbes Agro) interview with Novonesis CEO Ester Baiget during her COP30 visit to Brazil, published November 18, 2025 (in Portuguese; quotes below are translations).
- She frames the next transformation of the world economy as biological and says biosolutions should be worth US$877 billion and create more than 5 million jobs by 2035.
- Brazil is "in an excellent position to lead the power of biosolutions in the world", given resources, talent and the authorities' goodwill; she calls for regulation that builds a path for that future.
- Novonesis marked 50 years in Brazil, where it runs three plants (two near Curitiba, Paraná, one in Valinhos, São Paulo) plus R&D centres.
- Targets restated: up to 9% organic sales growth per year to 2030 and an adjusted EBITDA margin of 39%; she cites 8% organic growth and a 37.3% margin in the first nine months of 2025.
- Value levers named: replacing microplastics in detergents, higher bioethanol yields and more efficient corn oil extraction, while being a small fraction of customers' costs.
- According to the article, about 83% of revenue comes from solutions that contribute to the UN Sustainable Development Goals; she says emissions fell 62% since 2018 while revenue grew 25%.
Questions about Novonesis
What does Novonesis do?
Novonesis makes biosolutions (enzymes, cultures, probiotics, yeast, proteins and HMOs) by industrial fermentation for food, health, household care, agriculture and energy customers. It was formed by the combination of Novozymes and Chr. Hansen in January 2024.
What is Novonesis' revenue?
Net sales were EUR 4,157.6 million in 2025, with 7% organic growth. In the first nine months of 2026, net sales were EUR 3,375.6 million.
How many employees does Novonesis have?
Novonesis had 11,641 employees at the end of 2025, of which 5,104 in Denmark.
What is Novonesis' strategy?
The GROW strategy targets 6-9% organic sales CAGR and an adjusted EBITDA margin of ~39% by 2030, by growing the core, enhancing its position through innovation and scale, and accelerating the biosolutions market.
Who leads Novonesis?
Ester Baiget is President and CEO, Rainer Lehmann is CFO, and Cees de Jong chairs the board.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)